Health

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

While the drug was found to slow lung cancer worsening in patients, the absence of a survival benefit “does not support the positive benefit-risk profile in support of approval,” FDA reviewers concluded.

✦ Extractive summary — built from the sources' own reporting•From 2 sources•1 min read•Updated November 15, 2026, 8:33 PM UTC
Key points
  • The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.
  • In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved because it didn’t help patients live longer.
  • Continue to STAT+ to read the full story….

The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 2 articles from 2 outlets